Community-acquired pneumonia (CAP) is still an important complication in patients infected with HIV, even in the era of combined antiretroviral therapy (ART). 1 Patients with HIV are generally known to be more susceptible to pneumococcal infections with a higher rate of bacteremia than patients without HIV infection. 2 Several studies have examined microbial etiology and prognostic factors of CAP in patients with HIV. [3] [4] [5] [6] Despite the high rate of bacterial pneumonia in patients with HIV, mortality rates are not higher than in patients not infected with HIV.
The data on clinical presentation and outcomes of pneumococcal CAP in patients with HIV are limited and conflicting because these variables in patients with HIV are difficult to compare with those of not infected with HIV because bacterial pneumonia in patients not infected with HIV often occurs in older subjects than in the HIV population. 7 The incidence of bacterial pneumonia is related to immunological status in patients with HIV; despite the introduction of ART, however, the risk of invasive pneumococcal disease remains 35 times greater in HIV-infected patients than in similarly aged adults not infected with HIV. 8 Nevertheless, there are no data on whether clinical presentation and outcomes of pneumococcal CAP in patients with HIV with effective ART are similar to those of patients who are not infected. The hypothesis was that both clinical presentation and outcomes are similar. The aim of this study, therefore, was to investigate whether the clinical presentations and outcomes (length of stay [LOS] , ICU admission, and 30-day mortality) of pneumococcal pneumonia in virologically suppressed patients with HIV on ART with a CD4þ T-cell count > 350 cells/mm 3 are comparable to those seen in patients not infected with HIV, using a case-control design.
Patients and Methods

Study Design and Patients
A case-control study was carried out in Hospital Clinic, Barcelona, Spain. All consecutive cases of adult patients with a CAP diagnosis between January 2001 and January 2016 were included. CAP was defined as the presence of a new infiltrate on chest radiograph, together with clinical signs and symptoms suggestive of lower respiratory tract infection. Mycobacterial and fungal infections (other than Pneumocystis jiroveci) were recorded but not included in the analysis. The diagnosis of pneumococcal CAP was performed according to the following criteria: definite diagnosis, positive blood culture or positive pleural fluid culture or positive urinary antigen test for pneumococcus; and presumptive diagnosis, positive culture of respiratory samples (sputum, bronchoalveolar aspirate, and BAL) in patients with pulmonary infiltrates.
Case Patients, Control Patients, and Matched Criteria
Case patients were identified from the database of patients with CAP. Case patients were defined as HIV-infected adults (age, $ 18 years and # 50 years) with a diagnosis of pneumococcal pneumonia between 2001 and 2016, with a CD4 lymphocyte count $ 350 cells/mm 3 , and undetectable levels of HIV-RNA (copies/mL) on ART.
Two control cases of patients with pneumococcal pneumonia without HIV infection were selected for each case patient and matched for the following variables: age (age of the case patients at the time of pneumococcal CAP AE 10 years), sex, comorbidities (chronic respiratory disease, diabetes mellitus, neurological disease, chronic cardiovascular disease, chronic liver disease, chronic renal disease), and CAP diagnosis in the same calendar period.
This study was approved by the local institutional review board. Patients remained anonymous and informed consent was waived because of the observational nature of the study.
Study Variables
After case and control patients were identified, the following data were collected at the time of hospital admission: age, sex, HIV infection, AIDS-defining criteria, CD4þ cell count, plasma HIV viral load within the previous 3 months of admission, previous or current IV drug use, current smoking habits (> 10 pack-years), alcohol habits (ingestion of an estimated amount of > 80 g alcohol per day for at least 1 year before presentation), comorbidities (chronic respiratory disease, diabetes mellitus, neurological disease, chronic cardiovascular disease, chronic liver disease, chronic renal disease), antimicrobial treatment before hospital admission, ART, duration of symptoms before the diagnosis of pneumonia, physical examination clinical signs and symptoms (fever, cough, pleuritic pain, dyspnea, mental confusion, and aspiration, blood pressure, body temperature, respiratory rate, and heart rate), chest radiograph pattern (number of lobes affected, pleural effusion, and atelectasis), blood analysis (hemoglobin level, WBC count, platelet count, serum creatinine levels, C-reactive protein levels, and other biochemical parameters), pulmonary complications (empyema, ARDS criteria, pleural effusion, surgical pleural draining), clinical events (cardiac arrhythmia, septic shock, acute renal failure), and antimicrobial treatment at admission. Pneumonia severity index (PSI) and consciousness, urea, respiratory rate, BP, 65 years of age 9 scores were determined in all patients. 10 All surviving patients were visited or contacted by telephone within 30 days after discharge.
Microbiological Evaluation
Microbiological investigation was performed on sputum, urine, two blood samples, and nasopharyngeal swabs (e-Appendix). Pleural puncture, tracheobronchial aspirates, and BAL fluid, where available, were collected for Gram, Ziehl-Nielsen, May-Grünwald Giemsa, and Gomori methenamine silver stains and for cultures for bacterial, fungal, and mycobacterial pathogens.
Sputum and blood samples were obtained for bacterial culture before the start of antibiotic therapy in the ED. Nasopharyngeal swabs for respiratory virus detection and urine samples for Streptococcus pneumoniae and Legionella pneumophila antigen detection were obtained within 24 hours of admission to the hospital. Blood samples for serology of atypical pathogens and respiratory virus were performed at admission and at 4 to 6 weeks thereafter (e-Appendix).
HIV-1 viral load was determined by Versant HIV-1 RNA 1.0 kPCR (Siemens Diagnostics): lower limit of quantification: 37 copies/mL; upper limit of quantification: 11,000,000 copies/mL; lower limit of quantification in the period between 2007 and 2009 <50 copies/mL and in the period between 2010 and 2012 lower limit <37 copies/mL.
Statistical Analysis
A total sample size of 150 patients (50 patients in the case group and 100 in the control group, according to a 1:2 allocation ratio) was estimated to provide at least an 80% power and a two-sided alpha value of 0.05 to detect as statistically significant a difference of 25% in the percentage of patients admitted to ICU between groups (39% cases vs 14% control patients). 11 Data are shown as number of patients (%) for categorical variables and either median (interquartile range [IQR] ) for continuous variables with non-normal distribution or mean (SD) for those with normal distribution. Categorical variables were compared using the c 2 test or the Fisher exact test. Continuous variables were compared using the t test or the nonparametric Mann-Whitney test. Unconditional logistic regression analyses 12 were used to examine the associations between outcomes (ICU admission and prolonged LOS > 7 days [cutoff value is the median value of LOS]) and risk factors (see the full list of variables in the e-Appendix). First, each risk factor was tested individually, second, all risk factors which showed an association in the univariate model (P < .10) were added into the multivariate model, and, finally, a backward stepwise selection (P in < .05, P out < .10) was used to determine factors associated with ICU admission and prolonged LOS, with adjustment for one predefined covariate (ie, the case-control). The ORs and 95% CIs were calculated. The HosmerLemeshow goodness-of-fit test was performed to assess the overall fit of the models. 13 Internal validation of the prediction models was conducted using ordinary nonparametric bootstrapping with 1,000 bootstrap samples and bias-corrected, accelerated 95% CIs. 14 Receiver operating characteristic (ROC) curves were constructed for the ability to predict ICU admission and prolonged LOS using variables derived from the multivariate logistic regression models. Simple imputations of random effects were used, where necessary, for variables with missing values. The level of significance was set at .05 (2-tailed). All analyses were performed using IBM SPSS Statistics, version 22.0.
Results
General Patient Characteristics
During the study period (January 2001 to January 2016), 2,300 consecutive patients with CAP were admitted to the hospital. Of these, 525 (23%) were with HIV. Matching was successful in 50 cases and 100 control patients with CAP caused by S. pneumoniae.
Cases Characteristics
Of the 50 cases included, 35 (70%) were men, with a mean (SD) age of 46.5 (12.2) years. All cases were on ART, with the three most frequent ART regimens being two nucleoside analogue reverse transcriptase inhibitors (NRTIs) þ one integrase strand transfer inhibitor (18 and the proportion of patients with undetectable viral load was 100%. Nadir CD4þ cell count <200 cells/mL was 19 (39%). AIDS-defining illness was present in 23 (47%) of cases. The majority of patients (76%) were classified in the low-risk class (PSI risk class I-III). Seventeen patients (34%) presented coinfection with hepatitis C virus (HCV), hepatitis B virus (HBV), or both. The most frequent complications were multilobar pneumonia (16 patients [32%]) and bacteremia (24 patients [51%]). Nine patients (18%) were admitted to the ICU; six of these (12%) required mechanical ventilation. The median (IQR) LOS was 7.0 (5.0; 11.0) days. The overall 30-day mortality was 0%.
Comparison of Characteristics of Pneumonia Cases and Control Patients
Baseline characteristics comparing cases and control patients appear in Table 1 . Cases and control patients did not differ significantly in terms of baseline characteristics. Compared with the control cases, the case patients had higher rates of influenza and pneumococcal vaccination. The group of cases also presented a higher rate of coinfection with HBV. Also, coinfection with HCV seemed to be higher in the case group than the control group (Table 1) , but no statistically significant difference was found (P ¼ .059). The control group more frequently presented pleural pain as a symptom and pleural effusion as a complication when compared with case patients.
Microbiological Findings, Antimicrobial Resistance, and Pneumococcal Serotypes
Regarding microbiological diagnosis, 46 patients (92%) in the case group had a definitive diagnosis of pneumococcal pneumonia and 4 patients (8%) received a diagnosis via presumptive diagnosis. In the control group, 90 patients (90%) had a definitive diagnosis of pneumococcal pneumonia and 10 patients (10%) received a diagnosis via presumptive diagnosis. The percentages of patients with positive microbiological test results are shown in Minimal inhibitory concentration testing was performed in 82 of 121 of the S. pneumoniae isolates (68%). Eleven pneumococcal isolates showed some degree of penicillin nonsensitivity. In addition, 13 pneumococcal isolates Thirty-four of 69 invasive isolates (49%) were available for serotyping. The most frequent serotypes in the whole population were 1 (n ¼ 10, 29%), 7F (n ¼ 7, 21%), 9N (n ¼ 3, 9%), 3 (n ¼ 3, 9%), 19A (n ¼ 2, 6%), 14 (n ¼ 2, 6%), 13 (n ¼ 2, 6%), and 4 (n ¼ 4, 6%), as summarized in e- (Table 3) . 
Prognostic Factors
We performed univariate and multivariate analyses for ICU admission and prolonged LOS. In the first multivariate logistic regression analysis, the following factors were independently associated with ICU admission: PSI risk class IV-V, levels of lactate dehydrogenase < 498 U/L and the presence of multilobar involvement (Table 4 ). The area under the ROC curve was 0.81 (95% CI, 0.72-0.89) for the model predictive of ICU admission.
In the second multivariate logistic regression analysis for prolonged LOS (> 7 days), the following factors were independently associated: chronic lung disease, lactate dehydrogenase $ 498 U/L, multilobar involvement, pleural effusion, and invasive mechanical ventilation ( Table 5 ). The area under the ROC curve was 0.84 (95% CI, 0.78 to 0.91) for the model predictive of prolonged LOS (>7 days). HIV infection was not associated with ICU admission or increased LOS in the multivariate analysis, even after adjustments for case patients and potential confounding factors.
Internal validation of the two logistic regression models was conducted using bootstrapping with 1,000 samples.
All of the variables included in the models for ICU admission and prolonged LOS demonstrated robust results, with small 95% CIs around the original coefficients, except for invasive mechanical ventilation in the model for prolonged LOS, which appeared to be less reliable with wider 95% CIs around the original coefficients (e- Tables 3, 4) .
Discussion
This is believed to be the first case-control study addressing the issue of hospitalized pneumococcal CAP in virologically suppressed patients with HIV with > 350 CD4þ T cells/mm 3 . The most important finding of this study is that hospitalized patients with HIV with pneumococcal CAP did not have a more severe presentation or worse clinical outcome than uninfected patients. Also, in multivariate analysis, we found no evidence that HIV infection was a risk factor for ICU admission or longer LOS (>7 days).
There is conflicting information regarding clinical presentation and outcomes of hospitalized patients with HIV and CAP. 4, [16] [17] [18] Some studies have shown that mortality or LOS is unaffected by HIV infection, See Table 1 legend for expansion of abbreviation. Optimal cutoff value of cases and control patients using ROC curves.
whereas others have shown the opposite. Feldman et al 19 reported significant differences in the clinical presentation and outcome of bacteremic pneumococcal pneumonia when comparing patients with and without HIV. In this study, patients with HIV had more clinical symptoms, especially among those with lower CD4 cell counts. In this study, case patients presented with rates of bacteremia of nearly 50%. In a larger series from the present group on HIV and CAP (331 patients), published in 2014, 100 patients had pneumococcal CAP and 50% also had bacteremia. 6 Other series have reported rates of bacteremia ranging from 23% to 75%. 16, 20, 21 In the same way, Mayaud et al 7 reported differences in presentation of CAP between patients with and without HIV, high rates of bacteremia, and pleural effusion are presented in patients with HIV. Nevertheless, the study by Bordon et al 18 showed that clinical outcomes of patients with HIV with CAP are not predicted by CD4þ T-cell count or HIV-RNA levels; they comment that management of CAP in patients with HIV infection should not be made on the basis of CD4þ T-cell count or HIV-RNA levels of the HIV infection. Also, a secondary analysis of these data showed that the presence of HIV infection did not influence the clinical outcomes of CAP. 22 According to this study, there was no evidence that patients with HIV and pneumococcal pneumonia have a more severe presentation or worse clinical outcomes than patients not infected with HIV. These results are also in line with the present findings. We found that clinical presentations and outcomes are similar between virologically suppressed patients with and without HIV and with pneumococcal pneumonia.
The patients in this study were young, with mainly low severity scores. The mortality rate is not surprising and is low according to the PSI score, although this could be due to the specific population analyzed. Differences were found in the presence of chest pain and pleural effusion between case and control patients. Control patients presented higher frequencies of chest pain and pleural fluid with statistical differences compared with the case group. Also, we found that the serotypes (1, 19A, 3, 14, and 7F) described in the literature as being associated with complicated pneumococcal pneumonia 15 were more frequently observed in the control group (40% vs 83%; P ¼ .034). These results explain the higher rate of chest pain and pleural effusion and the higher percentages of empyema in the case group. Because the physician in charge of patients makes the thoracentesis decision directly, we do not have a clear explanation as to the low rate of thoracentesis in case patients. One possibility is the higher amount of radiographic pleural fluid observed in patients compared with control patients probably resulting from the concern of an alternative diagnosis in patients with HIV.
There are currently no specific guidelines or recommendations for virologically suppressed patients with HIV on ART with > 350 CD4 cells/mm 3 , and these results support the approach whereby these patients do not need specific treatments, hospital admission, or sites of care that are different from the general population.
Despite a higher rate of vaccination in the case group, only 10% and 14% of patients with HIV were vaccinated against pneumococcus and influenza, respectively. We did not find any association between pneumococcal vaccination and the rate of bacteremia in this study. This result highlights the importance of improving these vaccinations in the HIV population (as recommended by all international guidelines), in particular because most of the pneumococcus serotypes in the case group were included among those present in 13V pneumococcal vaccine.
Our study has a number of limitations. First, the defined sample size is too small to make a robust analysis of all related questions. The sample size calculation was made on the basis of the percentage of patients admitted to the ICU, in which a total sample size of 150 patients (50 patients in the case group and 100 patients in the control group, according to a 1:2 allocation ratio) is large enough if the expected difference is 25%. However, when comparing several characteristics between the two groups of patients (eg, outcomes), the current study was underpowered. Second, because the data were collected from a single academic teaching hospital in Spain, the results might not generalize to other patients admitted to other types of hospitals in other countries. Third, the study took place over a long period; the protocols and microbiologic procedures did not, however, substantially changed during those years. Finally, the low mortality ratio in the study limits the generalization of the results; however, there are no data in the literature showing that virologically suppressed patients with HIV on ART should be treated in the same way as patients not infected with HIV.
In conclusion, this study describes a subpopulation of hospitalized virologically suppressed patients with HIV on ART with > 350 CD4 cells/mm 3 and pneumococcal pneumonia in whom clinical presentation and outcomes did not differ from uninfected patients. The management of these patients with HIV should be the same as for HIV-uninfected individuals and should be included in the CAP management guidelines.
